ClinicalTrials.gg
CompletedNCT04129502Updated Oct 23, 2026

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

A Phase 3 interventional study of TAK-788 and Pemetrexed in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), sponsored by Takeda. Completed at 134 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

How we know

Updated Oct 23, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda — 1 open to participants now, 4 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Takeda.

Enrollment
2nd of 17
354 · median 101
Started
2020
with 2 others
Phase 3
3 of 31
none open now
Registered
17th of 31
by date

Among the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2020, is one of 3 in phase 3, and was the 17th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group.

Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.

Read the detailed description

The drug being tested in this study is called TAK-788. TAK-788 is being tested to evaluate the efficacy as a first line treatment compare with platinum-based chemotherapy in the participants with locally advanced or NSCLC whose tumors harbor EGFR exon 20 insertion mutations.

The study will enroll approximately 318 patients. Participants will be randomly assigned to one of the two treatment groups-

  • TAK-788 Group (Arm A)
  • Platinum-based Chemotherapy Group (Arm B)

The participants will be administered with TAK-788 orally in arm A and pemetrexed/cisplatin or pemetrexed/carboplatin intravenously (IV) in arm B until the participants experience progressive disease (PD) as assessed by blinded independent review committee (IRC), intolerable toxicity or another discontinuation criteria. Participants in the chemotherapy group may cross over to treatment with TAK-788 after IRC-assessed PD is documented. Randomized treatment with TAK-788 or platinum-based chemotherapy may be continued after PD, at the discretion of the investigator and with the sponsor's approval, if there is still evidence of clinical benefit.

This multi-center trial will be conducted in United States (US), Europe, and Asia. The overall time to participate in this study is until 3 years after the last participant is randomized. Participants will make multiple visits to the clinic and will be followed for survival, subsequent anticancer therapy, subsequent disease assessment outcome until disease progression on a subsequent anticancer therapy, and participant-reported health status (EuroQoL-5 Dimensions-5 Levels [EQ-5D-5L]) for 3 years after the last participant is randomized in the study and 30 days after the last dose of study drug for safety follow-up.

03

Conditions studied

  • Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adult patients (aged 18 years or older)
  • or cytologically confirmed nonsquamous cell locally advanced not suitable for definitive therapy, recurrent, or (Stage IV) NSCLC
  • Documented epidermal growth factor receptor (EGFR) in-frame exon 20 insertion mutation assessed by a clinical laboratory improvements amendment (CLIA)-certified (US sites) or an accredited (outside of the US) local laboratory The EGFR exon 20 insertion mutation can be either alone or in combination with other EGFR or human epidermal growth factor receptor 2 () mutations except EGFR mutations for which there are approved anti-EGFR tyrosine kinase inhibitors [TKIs] (ie, exon 19 del, L858R, T790M, L861Q, G719X, or S768I, where X is any other amino acid)
  • Adequate tumor tissue available, either from primary or metastatic sites, for central laboratory confirmation of EGFR exon 20 insertion mutation
  • At least 1 per Version 1.1
  • ≥3 months
  • (ECOG) performance status of 0 to 1
  • Adequate organ and hematologic function as defined by blood transfusions with a recommended >/ 14 day .

Exclusion criteria

Exclusion Criteria:

  • Received prior systemic treatment for locally advanced or disease, including local administration, such as intra-pleural injection of anticancer medication with the exception noted below:

    • or adjuvant chemotherapy/immune therapy for Stage I to III or combined modality chemotherapy/radiation for locally advanced disease is allowed if completed >6 months before the development of metastatic disease.
  • Received radiotherapy ≤14 days before randomization or has not recovered from radiotherapy-related toxicities
  • Received a moderate or strong cytochrome P450 (CYP)3A inhibitor or moderate or strong inducer within 10 days before first dose of TAK-788
  • Have been diagnosed with another primary other than NSCLC
  • Have current spinal cord compression or
  • Have uncontrolled hypertension. Participants with hypertension should be under treatment on study entry to control blood pressure
  • Received a within 4 weeks before randomization per Summary of product characteristics (SmPCs) for pemetrexed, cisplatin, and carboplatin
  • Taking medication(s) known to be associated with the development of torsades de pointes.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
354 participants (actual)

Study arms

  • Experimental
    TAK-788 Group (Arm A)

    TAK-788 160 milligram (mg) with or without food, capsules, orally, once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.

    Drug: TAK-788

  • Active comparator
    Platinum-based Chemotherapy Group (Arm B)

    Pemetrexed 500 milligram per meter square (mg/m\^2) plus cisplatin 75 mg/m\^2, infusion, IV, once on Day 1 of 21-day cycle pemetrexed 500 mg/m\^2 plus carboplatin, infusion, IV, once at a dose calculated to produce area under curve (AUC) of 5 milligram\*minute per milliliter (mg\*min/mL) on Day 1 of 21-day cycle until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria. Pemetrexed/cisplatin or pemetrexed/carboplatin will be repeated every 3 weeks for 4 cycles, followed by maintenance treatment with pemetrexed 500 mg/m\^2, on Day 1 of a 21-day cycle thereafter.

    Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    PFS is defined as the time interval from the date of randomization until the first date at which the criteria for progressive disease (PD) according to RECIST Version 1.1 are met or death, whichever occurs first.

    Time frame: Up to approximately 40 months after the first participant is randomized

Secondary outcomes

  1. Confirmed Objective Response Rate (ORR) as Assessed by Blinded Independent Review Committee (IRC) per RECIST Version 1.1

    Confirmed ORR is defined as the percentage of participants who are confirmed to have achieved complete response (CR) or partial response (PR). Confirmed responses are responses that persist on repeat imaging ≥4 weeks after initial response.

    Time frame: Up to approximately 40 months after the first participant is randomized

  2. Overall Survival (OS)

    OS is defined as the interval from the date of randomization until death.

    Time frame: Up to approximately 40 months after the first participant is randomized

  3. Progression Free Survival (PFS) as Assessed by the Investigator

    PFS is defined as the time interval from the date of randomization until the first date at which the criteria for PD according to RECIST Version 1.1 are met or death, whichever occurs first.

    Time frame: Up to approximately 40 months after the first participant is randomized

  4. Confirmed Objective Response Rate (ORR) as Assessed by the Investigator

    Confirmed ORR is defined as the percentage of participants who are confirmed to have achieved CR or PR. Confirmed responses are responses that persist on repeat imaging ≥4 weeks after initial response.

    Time frame: Up to approximately 40 months after the first participant is randomized

  5. Duration of Response, as Assessed by the Blinded Independent Review Committee (IRC) and the Investigator

    Duration of response is defined as the time interval from the time that the measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that PD or death (whichever occurs first) is objectively documented.

    Time frame: Up to approximately 40 months after the first participant is randomized

  6. Time to Response, as Assessed by the Blinded Independent Review Committee (IRC) and the Investigator

    Time to response is defined as the time interval from the date of randomization until the initial observation of CR or PR.

    Time frame: Up to approximately 40 months after the first participant is randomized

  7. Disease Control Rate (DCR) as Assessed by the Blinded Independent Review Committee (IRC) and the Investigator

    DCR is defined as the percentage of participants who have achieved CR, PR, or stable disease (SD) (in the case of SD, measurements must have met the SD criteria at least once after study entry at a minimum interval of 6 weeks) after the initiation of study drug.

    Time frame: Up to approximately 40 months after the first participant is randomized

  8. Patient-reported Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30

    EORTC QLQ-C30 is a cancer-specific questionnaire which comprises of 5 functional scales (physical, role, cognitive, emotional, and social functioning); 3 symptom scales (fatigue, pain, and nausea/vomiting); and a global health status/quality-of-life (QoL) scale. Six single-item scales are also included (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Raw scores will be converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QoL scale, higher scores represent better HRQoL, whereas for the symptom scales lower scores represent better HRQoL (i.e., a low level of symptomatology/problems).

    Time frame: Up to approximately 40 months after the first participant is randomized

  9. Participant-reported Symptoms as Assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire, Lung Cancer Module (QLQ-LC13)

    EORTC QLQ-LC13 is a cancer-specific questionnaire which comprises of 13 questions assessing lung cancer-associated symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and use of pain medication. Raw scores will be converted into scale scores ranging from 0 to 100. Higher scores represent a high level of symptomatology/problems.

    Time frame: Up to approximately 40 months after the first participant is randomized

07

Study locations

134 sites
  • City of Hope National Medical Center
    Long Beach, California 90813, United States
  • University of California Irvine
    Orange, California 92868, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • AdventHealth
    Orlando, Florida 32804, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Maryland Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Beth Israel Deaconess Medical Center - 330 Brookline Ave
    Boston, Massachusetts 02115, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • GenesisCare North Shore
    St Leonards, New South Wales 2065, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Klinik Floridsdorf
    Vienna, 1210, Austria
  • Cliniques Universitaires Saint-Luc
    Brussels, Brussels Capital 1200, Belgium
  • Grand Hopital de Charleroi asbl
    Charleroi, Hainaut 6000, Belgium
  • AZ Sint-Lucas
    Aalst, Oost-Vlaanderen 9300, Belgium
  • British Columbia Cancer Agency
    Vancouver, British Columbia V5Z-4E6, Canada
  • William Osler Health System
    Brampton, Ontario L6R 3J7, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G2M9, Canada
  • Hopital Du Sacre Coeur de Montreal
    Montreal, Quebec H4J 1C5, Canada
  • Beijing Cancer Hospital - PPDS
    Beijing, Beijing Municipality 100142, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130012, China
  • Beijing Cancer Hospital - PPDS
    Beijing, 100142, China
  • Beijing Chest Hospital, Capital Medical Univerity
    Beijing, 101149, China
  • Icahn School of Medicine at Mount Sinai
    Beijing, China
  • Sichuan Cancer Hospital & Institute
    Chengdu, 610041, China
  • Guangdong Provincial People's Hospital
    Guangzhou, 510080, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, 310003, China
  • Harbin Medical University Tumor Hospital
    Harbin, 150081, China
  • Shanghai East Hospital
    Shanghai, 200123, China
  • Hubei Cancer Hospital
    Wuhan, 430079, China
  • Centre Francois Baclesse
    Caen, Calvados 14076, France
  • CHU de Nantes - Hoptal Nord Laennec
    Nantes, Loire-Atlantique 44000, France
  • Hopital Calmette
    Lille, Nord 59037, France
  • Centre Leon Berard
    Lyon, Rhone 69373, France
  • Institut Gustave Roussy
    Villejuif, Val-de-Marne 94805, France
  • CHU de Grenoble
    Grenoble, 38043, France
  • Hopital Nord AP-HM
    Marseille, 13915, France
  • CRLC Val d'Aurelle - Paul Lamarque
    Montpellier, 34298, France
  • Hopital Tenon
    Paris, 75020, France
  • Nouvel Hopital Civil
    Strasbourg, 67091, France
  • Hopital Larrey
    Toulouse, 31059, France
  • Thoraxklinik-Heidelberg gGmbH
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • LMU Klinikum der Universitat Munchen
    München, Bavaria 80336, Germany
  • University Clinic Regensburg
    Regensburg, Bavaria 93053, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, Hesse 60596, Germany
  • Pius Hospital Oldenburg
    Oldenburg, Lower Saxony 26121, Germany
  • Helios Klinikum Emil Von Behring
    Berlin, 14165, Germany
  • Sotiria Chest Hospital of Athens
    Athens, Attica 11527, Greece
  • Bioclinic Thessaloniki (Galinos clinic)
    Thessaloniki, 546 29, Greece
  • Princess Margaret Hospital
    Kowloon City, Kowloon City, Hong Kong
  • Pamela Youde Nethersole Eastern Hospital
    Hong Kong, Hong Kong
  • Queen Elizabeth Hospital (QEH)
    Hong Kong, Hong Kong
  • Queen Mary Hospital - PPDS
    Hong Kong, Hong Kong
  • Tuen Mun Hospital
    Hong Kong, Hong Kong
  • Prince of Wales Hospital
    Shatin, Hong Kong
  • Soroka University Medical Centre
    Beersheba, 84101, Israel
  • Sheba Medical Center - PPDS
    Ramat Gan, 52621, Israel
  • AORN Dei Colli- Ospedale Monaldi Napoli
    Naples, Campania 80131, Italy
  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l - PPDS
    Meldola, Forli-Cesena 47014, Italy
  • Istituto Nazionale Dei Tumori
    Milan, Lombardy 20133, Italy
  • Instituto Europeo Di Oncologia
    Milan, Lombardy 20141, Italy
  • Azienda Sanitaria Ospedaliera S Luigi Gonzaga
    Orbassano, Piedmont 10043, Italy
  • Centro Di Riferimento Oncologico
    Aviano, Pordenone 33081, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, Tuscany 56124, Italy
  • Azienda Ospedaliero Universitaria di Parma
    Parma, 43126, Italy
  • Ospedale Santa Maria Delle Croci
    Ravenna, 48121, Italy
  • Fujita Health University Hospital
    Toyoake-Shi, Aiti 470-1101, Japan
  • National Cancer Center Hospital East
    Kashiwa-Shi, Chiba 277-0882, Japan
  • Ehime University Hospital
    Matsuyama, Ehime 791-0280, Japan
  • National Hospital Organization Hokkaido Cancer Center
    Sapporo, Hokkaido 003-0804, Japan
  • Kurume University Hospital
    Kurume-Shi, Hukuoka 830-0011, Japan
  • Kanagawa Cancer Center
    Yokohama, Kanagawa 241-0815, Japan
  • Saiseikai Kumamoto Hospital
    Kumamoto, Kumamoto 861-4101, Japan
  • Miyagi Cancer Center
    Natori-shi, Miyagi 981-1239, Japan
  • Okayama University Hospital
    Okayama, Okayama-ken 700-0914, Japan
  • Osaka International Cancer Institute
    Chuo Ku, Osaka 540-0008, Japan
  • Saitama Cancer Center
    Komoro, Saitama 362-0806, Japan
  • The Cancer Institute Hospital of Japanese Foundation For Cancer Research
    Koto-Ku, Tokyo 135-0063, Japan
  • VU Medisch Centrum
    Amsterdam, North Holland 1081 HV, Netherlands
  • Centro Hospitalar do Porto Hospital de Santo Antonio
    Santa Maria da Feira, Aveiro District 4520-211, Portugal
  • Hospital Cuf Porto
    Vila Nova de Gaia, Porto District 4434-502, Portugal
  • Centro Hospitalar de Lisboa Norte E.P.E Hospital Pulido Valente
    Lisbon, 1769-001, Portugal
  • Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
    Porto, 4200-072, Portugal
  • Centro Hospitalar de Sao Joao, E.P.E.
    Porto, 4200, Portugal
  • GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)
    Saint Petersburg, Leningradskaya Oblast' 197758, Russia
  • LLC "EuroCityClinic"
    Saint Petersburg, Sankt-Peterburg 197022, Russia
  • National Cancer Centre
    Singapore, 169608, Singapore
  • Chungbuk National University Hospital
    Cheongju-si, North Chungcheong 28644, South Korea
  • Pusan National University Hospital
    Busan, 602-739, South Korea
  • National Cancer Center
    Goyang, 410769, South Korea
  • Chonnam National University Hwasun Hospital
    Jeongnam, 519-763,, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Asan Medical Center - PPDS
    Seoul, 05505, South Korea
  • Samsung Medical Center PPDS
    Seoul, 06351, South Korea
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, South Korea
  • Severance Hospital Yonsei University Health System - PPDS
    Seoul, 120-752, South Korea

Showing the first 100 of 134 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Janne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, Peters S, Besse B, Pavlakis N, Neal JW, Kato T, Wu YL, Nguyen D, Lin J, Lin J, Vranceanu F, Szumski A, Lin HM, Fram RJ, Mok TSK. First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. J Clin Oncol. 2025 May;43(13):1553-1563. doi: 10.1200/JCO-24-01269. Epub 2025 Jan 29. PubMed 39879577 ↗

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Sep 2026, 80 months.

Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 80 months is above that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2019
First posted
Oct 16, 2019
StartActual
Jan 10, 2020
Primary completionActual
Sep 22, 2026was Oct 2026
CompletionActual
Sep 22, 2026was Oct 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 23, 2026
Primary completion
Oct 31, 2026→Sep 22, 2026 (actual)
Oct 23, 2026
Study completion
Oct 31, 2026→Sep 22, 2026 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Active, not recruiting→Completed
    Primary completion Oct 31, 2026→Sep 22, 2026 (now actual)
    Study completion Oct 31, 2026→Sep 22, 2026 (now actual)
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04129502
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 16, 2019
Start date
Jan 10, 2020
Primary completion
Sep 22, 2026
Completion
Sep 22, 2026
Last update
Oct 23, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mobocertinib

Start the discussion